II期临床-话题@MedSci

#II期临床#

478篇内容 | 2591人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1524787, encodeId=97791524e87dc, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=J Gastroenterology：维多珠单抗对日本克罗恩病患者的疗效影响——III期临床研究 , objectType=article, longId=189573, objectId=89671895e3b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89671895e3b8, replyNumber=0, likeNumber=46, createdTime=2020-03-10, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89671895e3b8, moduleTitle=J Gastroenterology：维多珠单抗对日本克罗恩病患者的疗效影响——III期临床研究 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89671895e3b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524786, encodeId=7ba61524e861b, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点, objectType=article, longId=189451, objectId=9d821894518e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d821894518e, replyNumber=0, likeNumber=13, createdTime=2020-03-07, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d821894518e, moduleTitle=Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d821894518e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524785, encodeId=c2b11524e859f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=J Clin Oncol：Pembrolizumab与Bevacizumab治疗转移肾细胞肿瘤的Ib/II期临床试验, objectType=article, longId=189176, objectId=3c381891e64b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c381891e64b, replyNumber=0, likeNumber=58, createdTime=2020-03-04, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c381891e64b, moduleTitle=J Clin Oncol：Pembrolizumab与Bevacizumab治疗转移肾细胞肿瘤的Ib/II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c381891e64b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524784, encodeId=4ecb1524e848c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NEJM：nemolizumab治疗中重度结节性瘙痒的II期临床取得积极结果, objectType=article, longId=188515, objectId=c1f8188515d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1f8188515d5, replyNumber=0, likeNumber=61, createdTime=2020-02-22, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1f8188515d5, moduleTitle=NEJM：nemolizumab治疗中重度结节性瘙痒的II期临床取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1f8188515d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524783, encodeId=94011524e833b, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=脑肿瘤一线治疗：VAL-083的II期临床试验即将开始, objectType=article, longId=188493, objectId=779818849367, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=779818849367, replyNumber=0, likeNumber=131, createdTime=2020-02-22, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=779818849367, moduleTitle=脑肿瘤一线治疗：VAL-083的II期临床试验即将开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=779818849367)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524782, encodeId=8ba51524e8232, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Incyte的JAK1/JAK2抑制剂ruxolitinib乳膏治疗特应性皮炎的第二个III期临床成功, objectType=article, longId=188485, objectId=ddfc1884854b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddfc1884854b, replyNumber=0, likeNumber=63, createdTime=2020-02-22, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddfc1884854b, moduleTitle=Incyte的JAK1/JAK2抑制剂ruxolitinib乳膏治疗特应性皮炎的第二个III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddfc1884854b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524781, encodeId=5d501524e81e1, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Verona Pharma公布ensifentrine作为慢性阻塞性肺病（COPD）维持治疗的II期临床结果, objectType=article, longId=188170, objectId=28501881e0e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28501881e0e2, replyNumber=0, likeNumber=77, createdTime=2020-02-17, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28501881e0e2, moduleTitle=Verona Pharma公布ensifentrine作为慢性阻塞性肺病（COPD）维持治疗的II期临床结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28501881e0e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524780, encodeId=a2521524e800e, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=默沙东宣布PD-1单抗Keytruda治疗三阴性乳腺癌的III期临床成功, objectType=article, longId=188050, objectId=0cde18805010, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cde18805010, replyNumber=0, likeNumber=71, createdTime=2020-02-16, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cde18805010, moduleTitle=默沙东宣布PD-1单抗Keytruda治疗三阴性乳腺癌的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cde18805010)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524779, encodeId=09aa1524e794f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=芬氟拉明治疗Lennox-Gastaut综合征的III期临床试验取得积极结果, objectType=article, longId=187677, objectId=e89218e67760, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e89218e67760, replyNumber=0, likeNumber=13, createdTime=2020-02-09, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e89218e67760, moduleTitle=芬氟拉明治疗Lennox-Gastaut综合征的III期临床试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e89218e67760)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524778, encodeId=d1801524e78ee, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=通用型流感疫苗M-001的II期临床试验取得积极结果, objectType=article, longId=187590, objectId=c62918e5909e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c62918e5909e, replyNumber=0, likeNumber=69, createdTime=2020-02-08, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c62918e5909e, moduleTitle=通用型流感疫苗M-001的II期临床试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c62918e5909e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524777, encodeId=71bd1524e77e0, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=用细菌抗击细菌！微生物群药物RBX2660已完成III期临床试验的注册, objectType=article, longId=187585, objectId=d55418e58511, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d55418e58511, replyNumber=0, likeNumber=47, createdTime=2020-02-08, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d55418e58511, moduleTitle=用细菌抗击细菌！微生物群药物RBX2660已完成III期临床试验的注册, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d55418e58511)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524776, encodeId=5c981524e7679, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=帕金森治疗或迎突破！CCR3抑制剂AKST4290开始II期临床试验, objectType=article, longId=187514, objectId=65e518e5149c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65e518e5149c, replyNumber=0, likeNumber=58, createdTime=2020-02-07, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65e518e5149c, moduleTitle=帕金森治疗或迎突破！CCR3抑制剂AKST4290开始II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65e518e5149c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524775, encodeId=96731524e75b4, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=卡泊三醇喷雾剂治疗牛皮癣的III期临床取得阳性结果, objectType=article, longId=186746, objectId=f965186e4626, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f965186e4626, replyNumber=0, likeNumber=76, createdTime=2020-01-27, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f965186e4626, moduleTitle=卡泊三醇喷雾剂治疗牛皮癣的III期临床取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f965186e4626)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524774, encodeId=cef31524e745e, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功, objectType=article, longId=186029, objectId=4575186029eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4575186029eb, replyNumber=0, likeNumber=22, createdTime=2020-01-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4575186029eb, moduleTitle=ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4575186029eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524773, encodeId=13891524e738b, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NEJM的：诺华的IgE单抗Ligelizumab在慢性自发性荨麻疹的III期临床中完胜奥马珠单抗, objectType=article, longId=186027, objectId=868418602e8e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=868418602e8e, replyNumber=0, likeNumber=66, createdTime=2020-01-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=868418602e8e, moduleTitle=NEJM的：诺华的IgE单抗Ligelizumab在慢性自发性荨麻疹的III期临床中完胜奥马珠单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=868418602e8e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524772, encodeId=20981524e72b5, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Apellis的C3补体抑制剂Pegcetacoplan用于阵发性夜间血红蛋白尿的III期临床成功, objectType=article, longId=185945, objectId=1f6e1859452d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f6e1859452d, replyNumber=0, likeNumber=72, createdTime=2020-01-10, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f6e1859452d, moduleTitle=Apellis的C3补体抑制剂Pegcetacoplan用于阵发性夜间血红蛋白尿的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f6e1859452d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524771, encodeId=bc2b1524e71da, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=默沙东的Keytruda治疗小细胞肺癌的III期临床，未能明显改善患者的总体生存率, objectType=article, longId=185921, objectId=fcce18592178, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcce18592178, replyNumber=0, likeNumber=94, createdTime=2020-01-10, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcce18592178, moduleTitle=默沙东的Keytruda治疗小细胞肺癌的III期临床，未能明显改善患者的总体生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcce18592178)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524770, encodeId=0ed31524e704c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点, objectType=article, longId=185843, objectId=5f5518584350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f5518584350, replyNumber=0, likeNumber=14, createdTime=2020-01-08, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f5518584350, moduleTitle=默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f5518584350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524769, encodeId=76101524e69cb, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=国产肝癌创新药多纳非尼一线治疗晚期肝细胞癌III期临床研究获得成功, objectType=article, longId=185534, objectId=9c1618553426, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c1618553426, replyNumber=0, likeNumber=65, createdTime=2020-01-03, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c1618553426, moduleTitle=国产肝癌创新药多纳非尼一线治疗晚期肝细胞癌III期临床研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c1618553426)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524768, encodeId=c41f1524e685b, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始, objectType=article, longId=185522, objectId=448618552283, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=448618552283, replyNumber=0, likeNumber=14, createdTime=2020-01-02, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=448618552283, moduleTitle=RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=448618552283)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

J Gastroenterology：维多珠单抗对日本克罗恩病患者的疗效影响——III期临床研究

2020-03-10

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点

2020-03-07

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

J Clin Oncol：Pembrolizumab与Bevacizumab治疗转移肾细胞肿瘤的Ib/II期临床试验

2020-03-04

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NEJM：nemolizumab治疗中重度结节性瘙痒的II期临床取得积极结果

2020-02-22

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

脑肿瘤一线治疗：VAL-083的II期临床试验即将开始

2020-02-22

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Incyte的JAK1/JAK2抑制剂ruxolitinib乳膏治疗特应性皮炎的第二个III期临床成功

2020-02-22

仁者大医 (审核中...)

前往app查看评论内容

#II期临床#

Verona Pharma公布ensifentrine作为慢性阻塞性肺病（COPD）维持治疗的II期临床结果

2020-02-17

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

默沙东宣布PD-1单抗Keytruda治疗三阴性乳腺癌的III期临床成功

2020-02-16

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

芬氟拉明治疗Lennox-Gastaut综合征的III期临床试验取得积极结果

2020-02-09

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

通用型流感疫苗M-001的II期临床试验取得积极结果

2020-02-08

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

用细菌抗击细菌！微生物群药物RBX2660已完成III期临床试验的注册

2020-02-08

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

帕金森治疗或迎突破！CCR3抑制剂AKST4290开始II期临床试验

2020-02-07

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

卡泊三醇喷雾剂治疗牛皮癣的III期临床取得阳性结果

2020-01-27

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功

2020-01-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NEJM的：诺华的IgE单抗Ligelizumab在慢性自发性荨麻疹的III期临床中完胜奥马珠单抗

2020-01-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Apellis的C3补体抑制剂Pegcetacoplan用于阵发性夜间血红蛋白尿的III期临床成功

2020-01-10

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

默沙东的Keytruda治疗小细胞肺癌的III期临床，未能明显改善患者的总体生存率

2020-01-10

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点

2020-01-08

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

国产肝癌创新药多纳非尼一线治疗晚期肝细胞癌III期临床研究获得成功

2020-01-03

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始

2020-01-02

科室
- - 订阅+
  - 更多科室
工具
服务